Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217502485> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3217502485 abstract "Peripheral artery disease (PAD) is caused by atherosclerotic occlusion of vessels outside the heart and most commonly affects vessels of the lower extremities. Angiogenesis is a part of the post ischemic adaption involved in restoring blood flow in PAD. Previously, in a murine hind limb ischemia (HLI) model of PAD, we identified ADAM12 as a key genetic modifier of post-ischemic perfusion recovery. However, less is known about ADAM12 regulation in ischemia. MiRNAs are a class of small, non-coding, single-stranded RNAs that regulate gene expression primarily through transcriptional repression of mRNA. We showed miR29a modulates ADAM12 expression in the setting of type 1 DM and ischemia. However, how miR29a modulates ADAM12 was not known. Moreover, the physiological effects of miR29a modulation in a non-diabetic setting was not known. Here, we demonstrate that AAV-mediated ectopic overexpression of miR29a in ischemic mouse hind limbs impairs post ischemic perfusion recovery and angiogenesis. We further demonstrate that miR29a regulates ADAM12 through direct interaction with ADAM12 mRNA. Treatment of ischemic mouse hind limbs with AAV9 particles containing miR29a (pAV-miR29a) increased miR29a expression (pAV-control vs pAV-miR29a: 3.22 ± 0.36, vs 1.0 ± 0.09, p<0.05, n=5-6,) and decreased ADAM12 mRNA expression (1.0 ± 0.31 vs 0.30 ± 0.08, p<0.05, n=7-10) resulting in decreased angiogenesis (1.0 ± 0.07 vs 0.66 ± 0.04, p<0.05, n=5), and impairment perfusion (week 3 post HLI perfusion, 101.9±5.55 vs 66.13±12.39, p<0.05, n=5-6,).AGO2 miRNA/RNA-immunoprecipitation studies showed levels of miR29a and ADAM12 mRNA in the complex decreased in samples treated with antagomiR29a (4, 40, 400nM) in a dose dependent manner (miR29a: 0.87, 0.68, 0.44, and ADAM12: 0.89, 0.78, 0.67, fold) but was unchanged by control antagomir (miR29a: 0.84, 0.84, 0.87, fold, and ADAM12: 1.11, 1.12, 1.10, fold). Taken together the data shows miR29a suppresses ADAM12 expression by directly binding to its mRNA resulting in impaired angiogenesis and poor perfusion. Hence, elevated levels of miR29a as seen in diabetes likely contributes to vascular pathology and lowering miR29a could be a therapeutic target." @default.
- W3217502485 created "2021-12-06" @default.
- W3217502485 creator A5002113693 @default.
- W3217502485 creator A5038646490 @default.
- W3217502485 creator A5063500342 @default.
- W3217502485 creator A5064042285 @default.
- W3217502485 creator A5064908010 @default.
- W3217502485 date "2021-11-16" @default.
- W3217502485 modified "2023-10-17" @default.
- W3217502485 title "Abstract 13466: In Experimental Pad miR29a Modulates Perfusion Recovery and ADAM12 Expression Through Direct Interaction With ADAM12 mRNA" @default.
- W3217502485 doi "https://doi.org/10.1161/circ.144.suppl_1.13466" @default.
- W3217502485 hasPublicationYear "2021" @default.
- W3217502485 type Work @default.
- W3217502485 sameAs 3217502485 @default.
- W3217502485 citedByCount "0" @default.
- W3217502485 crossrefType "journal-article" @default.
- W3217502485 hasAuthorship W3217502485A5002113693 @default.
- W3217502485 hasAuthorship W3217502485A5038646490 @default.
- W3217502485 hasAuthorship W3217502485A5063500342 @default.
- W3217502485 hasAuthorship W3217502485A5064042285 @default.
- W3217502485 hasAuthorship W3217502485A5064908010 @default.
- W3217502485 hasConcept C104317684 @default.
- W3217502485 hasConcept C105580179 @default.
- W3217502485 hasConcept C126322002 @default.
- W3217502485 hasConcept C142724271 @default.
- W3217502485 hasConcept C145059251 @default.
- W3217502485 hasConcept C146957229 @default.
- W3217502485 hasConcept C150194340 @default.
- W3217502485 hasConcept C164705383 @default.
- W3217502485 hasConcept C2777408375 @default.
- W3217502485 hasConcept C2780394083 @default.
- W3217502485 hasConcept C51738704 @default.
- W3217502485 hasConcept C541997718 @default.
- W3217502485 hasConcept C54355233 @default.
- W3217502485 hasConcept C71924100 @default.
- W3217502485 hasConcept C86803240 @default.
- W3217502485 hasConceptScore W3217502485C104317684 @default.
- W3217502485 hasConceptScore W3217502485C105580179 @default.
- W3217502485 hasConceptScore W3217502485C126322002 @default.
- W3217502485 hasConceptScore W3217502485C142724271 @default.
- W3217502485 hasConceptScore W3217502485C145059251 @default.
- W3217502485 hasConceptScore W3217502485C146957229 @default.
- W3217502485 hasConceptScore W3217502485C150194340 @default.
- W3217502485 hasConceptScore W3217502485C164705383 @default.
- W3217502485 hasConceptScore W3217502485C2777408375 @default.
- W3217502485 hasConceptScore W3217502485C2780394083 @default.
- W3217502485 hasConceptScore W3217502485C51738704 @default.
- W3217502485 hasConceptScore W3217502485C541997718 @default.
- W3217502485 hasConceptScore W3217502485C54355233 @default.
- W3217502485 hasConceptScore W3217502485C71924100 @default.
- W3217502485 hasConceptScore W3217502485C86803240 @default.
- W3217502485 hasIssue "Suppl_1" @default.
- W3217502485 hasLocation W32175024851 @default.
- W3217502485 hasOpenAccess W3217502485 @default.
- W3217502485 hasPrimaryLocation W32175024851 @default.
- W3217502485 hasRelatedWork W1202594152 @default.
- W3217502485 hasRelatedWork W1980989300 @default.
- W3217502485 hasRelatedWork W2070176548 @default.
- W3217502485 hasRelatedWork W2133028090 @default.
- W3217502485 hasRelatedWork W2150018887 @default.
- W3217502485 hasRelatedWork W2174711870 @default.
- W3217502485 hasRelatedWork W2276950657 @default.
- W3217502485 hasRelatedWork W2383963302 @default.
- W3217502485 hasRelatedWork W2913371005 @default.
- W3217502485 hasRelatedWork W4285370733 @default.
- W3217502485 hasVolume "144" @default.
- W3217502485 isParatext "false" @default.
- W3217502485 isRetracted "false" @default.
- W3217502485 magId "3217502485" @default.
- W3217502485 workType "article" @default.